表紙
市場調査レポート

HIV/AIDS:パイプライン製品の分析

HIV / AIDS - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232769
出版日 ページ情報 英文 886 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
HIV/AIDS:パイプライン製品の分析 HIV / AIDS - Pipeline Review, H1 2016
出版日: 2016年06月30日 ページ情報: 英文 886 Pages
概要

HIV とは、免疫システムを攻撃するウィルスのことで、感染症や疾患と戦う体内の力を弱めてしまいます。症状は熱、のどの痛み、体中の発疹、関節痛、筋肉痛、腺の肥大などが見られます。HIVの感染が一番拡大しやすいのは、HIV/AIDS感染者との避妊具を使わない性交や、感染者と注射針を共有したり、HIVのついた外科用器具で体に深い傷がついたり、HIVに感染している血液、体液などが開いた傷口などから入ってくることなどです。

当レポートでは、HIV / AIDS の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

HIV / AIDS 概要

治療薬の開発

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

治療薬の評価

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7958IDB

Summary

Global Markets Direct's, 'HIV / AIDS - Pipeline Review, H1 2016', provides an overview of the HIV / AIDS pipeline landscape.

The report provides comprehensive information on the therapeutics under development for HIV / AIDS, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for HIV / AIDS and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of HIV / AIDS
  • The report reviews pipeline therapeutics for HIV / AIDS by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved HIV / AIDS therapeutics and enlists all their major and minor projects
  • The report assesses HIV / AIDS therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for HIV / AIDS

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for HIV / AIDS
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding HIV / AIDS pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • HIV / AIDS Overview
  • Therapeutics Development
  • HIV / AIDS - Therapeutics under Development by Companies
  • HIV / AIDS - Therapeutics under Investigation by Universities/Institutes
  • HIV / AIDS - Pipeline Products Glance
  • HIV / AIDS - Products under Development by Companies
  • HIV / AIDS - Products under Investigation by Universities/Institutes
  • HIV / AIDS - Companies Involved in Therapeutics Development
  • HIV / AIDS - Therapeutics Assessment
  • Drug Profiles
  • HIV / AIDS - Dormant Projects
  • HIV / AIDS - Discontinued Products
  • HIV / AIDS - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for HIV / AIDS, H1 2016
  • Number of Products under Development for HIV / AIDS - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..5)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..5)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..6)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..7)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..8)
  • HIV / AIDS - Pipeline by Abivax S.A., H1 2016
  • HIV / AIDS - Pipeline by AdAlta Pty Ltd., H1 2016
  • HIV / AIDS - Pipeline by Advanced Genetic Systems, Inc., H1 2016
  • HIV / AIDS - Pipeline by Akshaya Bio Inc., H1 2016
  • HIV / AIDS - Pipeline by AlbaJuna Therapeutics, H1 2016
  • HIV / AIDS - Pipeline by Altor BioScience Corporation, H1 2016
  • HIV / AIDS - Pipeline by Altravax, Inc., H1 2016
  • HIV / AIDS - Pipeline by Amarna Therapeutics B.V., H1 2016
  • HIV / AIDS - Pipeline by American Gene Technologies International Inc., H1 2016
  • HIV / AIDS - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2016
  • HIV / AIDS - Pipeline by Amunix Operating Inc. , H1 2016
  • HIV / AIDS - Pipeline by Antigen Express, Inc., H1 2016
  • HIV / AIDS - Pipeline by Aphios Corporation, H1 2016
  • HIV / AIDS - Pipeline by Apotex Inc., H1 2016
  • HIV / AIDS - Pipeline by Argos Therapeutics, Inc., H1 2016
  • HIV / AIDS - Pipeline by Arno Therapeutics, Inc., H1 2016
  • HIV / AIDS - Pipeline by Avexa Limited, H1 2016
  • HIV / AIDS - Pipeline by BCI Pharma, H1 2016
  • HIV / AIDS - Pipeline by BioClonetics Immunotherapeutics, Inc., H1 2016
  • HIV / AIDS - Pipeline by Bionor Pharma ASA, H1 2016
  • HIV / AIDS - Pipeline by Biosantech SA, H1 2016
  • HIV / AIDS - Pipeline by Biotron Limited, H1 2016
  • HIV / AIDS - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • HIV / AIDS - Pipeline by C4X Discovery Holdings PLC, H1 2016
  • HIV / AIDS - Pipeline by CEL-SCI Corporation, H1 2016
  • HIV / AIDS - Pipeline by Celgene Corporation, H1 2016
  • HIV / AIDS - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • HIV / AIDS - Pipeline by Chipscreen Biosciences Ltd, H1 2016
  • HIV / AIDS - Pipeline by CompleGen, Inc., H1 2016
  • HIV / AIDS - Pipeline by ContraVir Pharmaceuticals, Inc., H1 2016
  • HIV / AIDS - Pipeline by Critical Outcome Technologies Inc., H1 2016
  • HIV / AIDS - Pipeline by CureVac GmbH, H1 2016
  • HIV / AIDS - Pipeline by Cytodyn Inc., H1 2016
  • HIV / AIDS - Pipeline by Enzo Biochem, Inc., H1 2016
  • HIV / AIDS - Pipeline by EpiVax, Inc., H1 2016
  • HIV / AIDS - Pipeline by eTheRNA Immunotherapies NV, H1 2016
  • HIV / AIDS - Pipeline by Etubics Corporation, H1 2016
  • HIV / AIDS - Pipeline by Evofem, Inc., H1 2016
  • HIV / AIDS - Pipeline by FIT Biotech Oy, H1 2016
  • HIV / AIDS - Pipeline by Formune S.L., H1 2016
  • HIV / AIDS - Pipeline by Fountain Biopharma Inc., H1 2016
  • HIV / AIDS - Pipeline by Frontier Biotechnologies Co., Ltd, H1 2016
  • HIV / AIDS - Pipeline by GeneCure LLC, H1 2016
  • HIV / AIDS - Pipeline by Genetic Immunity, Inc, H1 2016
  • HIV / AIDS - Pipeline by Genticel S.A., H1 2016
  • HIV / AIDS - Pipeline by GeoVax Labs, Inc., H1 2016
  • HIV / AIDS - Pipeline by Gilead Sciences, Inc., H1 2016
  • HIV / AIDS - Pipeline by GlaxoSmithKline Plc, H1 2016
  • HIV / AIDS - Pipeline by Globeimmune, Inc., H1 2016
  • HIV / AIDS - Pipeline by H-Phar S.A., H1 2016
  • HIV / AIDS - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2016
  • HIV / AIDS - Pipeline by Heat Biologics, Inc., H1 2016
  • HIV / AIDS - Pipeline by iCo Therapeutics Inc., H1 2016
  • HIV / AIDS - Pipeline by ID Pharma Co., Ltd., H1 2016
  • HIV / AIDS - Pipeline by Immune Response BioPharma, Inc., H1 2016
  • HIV / AIDS - Pipeline by Immunocore Limited, H1 2016
  • HIV / AIDS - Pipeline by ImQuest Life Sciences, H1 2016
  • HIV / AIDS - Pipeline by InnaVirVax SA, H1 2016
  • HIV / AIDS - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
  • HIV / AIDS - Pipeline by Japan Tobacco Inc., H1 2016
  • HIV / AIDS - Pipeline by Johnson & Johnson, H1 2016
  • HIV / AIDS - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • HIV / AIDS - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2016
  • HIV / AIDS - Pipeline by Longevity Biotech, Inc, H1 2016
  • HIV / AIDS - Pipeline by MacroGenics, Inc., H1 2016
  • HIV / AIDS - Pipeline by Medestea Research & Production S.p.A., H1 2016
  • HIV / AIDS - Pipeline by Medivir AB, H1 2016
  • HIV / AIDS - Pipeline by Merck & Co., Inc., H1 2016
  • HIV / AIDS - Pipeline by Mologen AG, H1 2016
  • HIV / AIDS - Pipeline by Mymetics Corporation, H1 2016
  • HIV / AIDS - Pipeline by Myrexis, Inc., H1 2016
  • HIV / AIDS - Pipeline by NanoBio Corporation, H1 2016
  • HIV / AIDS - Pipeline by NanoViricides, Inc., H1 2016
  • HIV / AIDS - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016
  • HIV / AIDS - Pipeline by NeED Pharma s.r.l., H1 2016
  • HIV / AIDS - Pipeline by New World Laboratories, Inc., H1 2016
  • HIV / AIDS - Pipeline by Novartis AG, H1 2016
  • HIV / AIDS - Pipeline by Omeros Corporation, H1 2016
  • HIV / AIDS - Pipeline by Oncolys BioPharma Inc., H1 2016
  • HIV / AIDS - Pipeline by OncoNOx ApS, H1 2016
  • HIV / AIDS - Pipeline by Oncovir, Inc., H1 2016
  • HIV / AIDS - Pipeline by Orbis Biosciences, Inc., H1 2016
  • HIV / AIDS - Pipeline by Osel, Inc., H1 2016
  • HIV / AIDS - Pipeline by OyaGen Inc., H1 2016
  • HIV / AIDS - Pipeline by PaxVax, Inc., H1 2016
  • HIV / AIDS - Pipeline by Pepscan Therapeutics, H1 2016
  • HIV / AIDS - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2016
  • HIV / AIDS - Pipeline by Pfizer Inc., H1 2016
  • HIV / AIDS - Pipeline by Pharis Biotec GmbH, H1 2016
  • HIV / AIDS - Pipeline by Pharmsynthez, H1 2016
  • HIV / AIDS - Pipeline by Phoenix Biotechnology, Inc., H1 2016
  • HIV / AIDS - Pipeline by Polymun Scientific Immunbiologische Forschung GmbH, H1 2016
  • HIV / AIDS - Pipeline by Presidio Pharmaceuticals, Inc., H1 2016
  • HIV / AIDS - Pipeline by Profectus BioSciences, Inc., H1 2016
  • HIV / AIDS - Pipeline by ReceptoPharm, Inc., H1 2016
  • HIV / AIDS - Pipeline by Rodos BioTarget GmbH, H1 2016
  • HIV / AIDS - Pipeline by Sangamo BioSciences, Inc., H1 2016
  • HIV / AIDS - Pipeline by Sanofi, H1 2016
  • HIV / AIDS - Pipeline by Sanofi Pasteur SA, H1 2016
  • HIV / AIDS - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016
  • HIV / AIDS - Pipeline by SEEK Group, H1 2016
  • HIV / AIDS - Pipeline by Serometrix, LLC, H1 2016
  • HIV / AIDS - Pipeline by Sirenas Marine Discovery LLC, H1 2016
  • HIV / AIDS - Pipeline by Spider Biotech, H1 2016
  • HIV / AIDS - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016
  • HIV / AIDS - Pipeline by Staidson (Beijing) Biopharmaceuticals Co., Ltd., H1 2016
  • HIV / AIDS - Pipeline by Starpharma Holdings Limited, H1 2016
  • HIV / AIDS - Pipeline by Susavion Biosciences, Inc., H1 2016
  • HIV / AIDS - Pipeline by Taiga Biotechnologies, Inc., H1 2016
  • HIV / AIDS - Pipeline by TaiMed Biologics Inc., H1 2016
  • HIV / AIDS - Pipeline by Takara Bio Inc., H1 2016
  • HIV / AIDS - Pipeline by TechnoVax, Inc., H1 2016
  • HIV / AIDS - Pipeline by TeneoBio Inc, H1 2016
  • HIV / AIDS - Pipeline by TetraLogic Pharmaceuticals, H1 2016
  • HIV / AIDS - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • HIV / AIDS - Pipeline by TGV-Laboratories, H1 2016
  • HIV / AIDS - Pipeline by Theraclone Sciences, Inc., H1 2016
  • HIV / AIDS - Pipeline by Theravectys SA, H1 2016
  • HIV / AIDS - Pipeline by Tobira Therapeutics, Inc., H1 2016
  • HIV / AIDS - Pipeline by Tomegavax, Inc., H1 2016
  • HIV / AIDS - Pipeline by Transgene Biotek Limited, H1 2016
  • HIV / AIDS - Pipeline by TVAX Biomedical, Inc., H1 2016
  • HIV / AIDS - Pipeline by United Biomedical, Inc., H1 2016
  • HIV / AIDS - Pipeline by United Therapeutics Corporation, H1 2016
  • HIV / AIDS - Pipeline by Vaccibody AS, H1 2016
  • HIV / AIDS - Pipeline by Vault Pharma Inc., H1 2016
  • HIV / AIDS - Pipeline by VDA Pharma, Inc., H1 2016
  • HIV / AIDS - Pipeline by VG Life Sciences, Inc., H1 2016
  • HIV / AIDS - Pipeline by Vichem Chemie Research Ltd., H1 2016
  • HIV / AIDS - Pipeline by ViiV Healthcare Limited, H1 2016
  • HIV / AIDS - Pipeline by Viriom Ltd., H1 2016
  • HIV / AIDS - Pipeline by ViroStatics srl, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • HIV / AIDS - Dormant Projects, H1 2016
  • HIV / AIDS - Dormant Projects (Contd..1), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..2), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..3), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..4), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..5), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..6), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..7), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..8), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..9), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..10), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..11), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..12), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..13), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..14), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..15), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..16), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..17), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..18), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..19), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..20), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..21), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..22), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..23), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..24), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..25), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..26), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..27), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..28), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..29), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..30), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..31), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..32), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..33), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..34), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..35), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..36), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..37), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..38), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..39), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..40), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..41), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..42), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..43), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..44), H1 2016
  • HIV / AIDS - Discontinued Products, H1 2016
  • HIV / AIDS - Discontinued Products (Contd..1), H1 2016
  • HIV / AIDS - Discontinued Products (Contd..2), H1 2016
  • HIV / AIDS - Discontinued Products (Contd..3), H1 2016
  • HIV / AIDS - Discontinued Products (Contd..4), H1 2016
  • HIV / AIDS - Discontinued Products (Contd..5), H1 2016
  • HIV / AIDS - Discontinued Products (Contd..6), H1 2016

List of Figures

  • Number of Products under Development for HIV / AIDS, H1 2016
  • Number of Products under Development for HIV / AIDS - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top